Endoscopic Injection Sclerotherapy Versus NCT03388125

Clinical Trial Details — Status: Active, not recruiting

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Recruitment information / eligibility
Status	Active, not recruiting
Enrollment	113
Est. completion date	December 1, 2022
Est. primary completion date	August 1, 2017
Accepts healthy volunteers	No
Gender	All
Age group	N/A and older
Eligibility	Inclusion Criteria: - cirrhotic patients presented with actively bleeding Exclusion Criteria: - other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)

Drug:
• Injection Sclerotherapy
5% ethanolamine oleate group
• N-butyl-2-cyanoacrylate
N-butyl-2-cyanoacrylate injection group

Locations
Country	Name	City	State
Egypt	Sherief Abd-Elsalam	Tanta

Sponsors *(1)*
Lead Sponsor	Collaborator
Sherief Abd-Elsalam

Egypt,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with controlled bleeding	The Number of patients with controlled bleeding	6 months

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03624517` - Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices	Phase 4
Completed	`NCT02475122` - Prognostic Value of Measuring DsAz by MRI in Cirrhotic Patients on Prophylactic Treatment With β Blocker (AzyMR)	N/A
Completed	`NCT01095185` - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding	Phase 3
Recruiting	`NCT02853526` - TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV	Phase 3
Recruiting	`NCT01970748` - Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices	Phase 4